BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis

Autor: Kai Liu, Weiling Fu, Qing Huang, Liqun Zhang, Yunxia Wang, Jun-Fu Huang, Zheng-Ran Chuai, Zhao Yang, Da-Chuan Shi, Dong Chen
Jazyk: angličtina
Rok vydání: 2014
Předmět:
Oncology
Epidemiology
Colorectal cancer
Pathological staging
lcsh:Medicine
Signal transduction
Bioinformatics
Proto-Oncogene Mas
Molecular cell biology
Pathology
Odds Ratio
Clinical Epidemiology
lcsh:Science
Multidisciplinary
Cancer Risk Factors
Signaling cascades
Genetic Epidemiology
Meta-analysis
Mutation (genetic algorithm)
Medicine
Colorectal Neoplasms
Cancer Epidemiology
Research Article
Genetic Markers
Proto-Oncogene Proteins B-raf
medicine.medical_specialty
MAPK signaling cascades
Systematic Reviews
Clinical Research Design
Genetic Causes of Cancer
Mutation
Missense
Biology
MLH1
Chemoprevention
Rectal Cancer
Diagnostic Medicine
Internal medicine
Gastrointestinal Tumors
medicine
Humans
neoplasms
Genetic Association Studies
CpG Island Methylator Phenotype
lcsh:R
Cancers and Neoplasms
Microsatellite instability
Odds ratio
medicine.disease
digestive system diseases
Biomarker Epidemiology
lcsh:Q
Zdroj: PLoS ONE, Vol 9, Iss 3, p e90607 (2014)
PLoS ONE
ISSN: 1932-6203
Popis: Background Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying causative genetic mutations. The B-type Raf proto-oncogene (BRAF) plays an important role in the mitogen-activated protein kinase (MAPK) signaling cascade during CRC. The presence of BRAFV600E mutation can determine the response of a tumor to chemotherapy. However, the association between the BRAFV600E mutation and the clinicopathological features of CRC remains controversial. We performed a systematic review and meta-analysis to estimate the effect of BRAFV600E mutation on the clinicopathological characteristics of CRC. Methods We identified studies that examined the effect of BRAFV600E mutation on CRC within the PubMed, ISI Science Citation Index, and Embase databases. The effect of BRAFV600E on outcome parameters was estimated by odds ratios (ORs) with 95% confidence intervals (CIs) for each study using a fixed effects or random effects model. Results 25 studies with a total of 11,955 CRC patients met inclusion criteria. The rate of BRAFV600 was 10.8% (1288/11955). The BRAFV600E mutation in CRC was associated with advanced TNM stage, poor differentiation, mucinous histology, microsatellite instability (MSI), CpG island methylator phenotype (CIMP). This mutation was also associated with female gender, older age, proximal colon, and mutL homolog 1 (MLH1) methylation. Conclusions This meta-analysis demonstrated that BRAFV600E mutation was significantly correlated with adverse pathological features of CRC and distinct clinical characteristics. These data suggest that BRAFV600E mutation could be used to supplement standard clinical and pathological staging for the better management of individual CRC patients, and could be considered as a poor prognostic marker for CRC.
Databáze: OpenAIRE
Externí odkaz: